Ascentage Pharma Group International
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Dajun Yang
- Full Time Employees
- 767
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Suzhou Industrial Park Suzhou JS China 215000
- IPO Date
- Oct 28, 2019
- Website
- ascentage.com
- Similar Companies
- Business
- Ascentage Pharma Group International (6855.HK) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies targeting apoptosis regulators for cancers, chronic hepatitis B, and age-related diseases; its core pipeline includes nine clinical-stage candidates such as the third-generation BCR-ABL inhibitor olverembatinib (HQP1351/耐立克®) for drug-resistant chronic myeloid leukemia, the Bcl-2 selective inhibitor lisaftoclax (APG-2575), the dual Bcl-2/Bcl-xL inhibitor pelcitoclax (APG-1252), the MDM2-p53 inhibitor alrizomadlin (APG-115), IAP inhibitors, next-generation tyrosine kinase inhibitors including ALK and FAK inhibitors, and epigenome-modifying agents like an EED inhibitor. The company conducts over 40 clinical trials across the US, Australia, Europe, and China, including eleven registrational trials with two FDA-regulated; it serves primarily hematologic malignancies such as chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and multiple myeloma, as well as solid tumors and other indications. Founded in 2009 and headquartered in Suzhou, China, with additional operations in Rockville, Maryland, USA, Ascentage Pharma maintains global partnerships with entities including Takeda, AstraZeneca, MSD, Pfizer, and Innovent Biologics. Recent developments include the closing of a US$75 million equity investment from Takeda in June 2024 as part of a US$1.3 billion licensing deal for olverembatinib; US FDA clearance for a global Phase III trial of olverembatinib in February 2024; a US$190.1 million financing round in July 2025; and a US$126 million Nasdaq IPO in January 2025 under ticker AAPG, alongside ongoing collaborations such as with AstraZeneca for APG-2575 in CLL/SLL.
Company News
Ascentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
Ascentage Pharma Stock Could More Than Double: Analyst
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 4% – Should You Buy?
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives Average Recommendation of “Buy” from Brokerages
Ascentage Pharma Group International (NASDAQ:AAPG) Sets New 12-Month Low – Time to Sell?
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript
Ascentage Pharma Group International H1 Earnings Call Highlights
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Still a Buy?
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
Wall Street Analysts Predict a 160.09% Upside in Ascentage Pharma Group International - Unsponsored ADR (AAPG): Here's What You Should Know
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
How Much Upside is Left in Ascentage Pharma Group International - Unsponsored ADR (AAPG)? Wall Street Analysts Think 152.23%
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress